Aim Our goal was to investigate the use of hypnosedatives (HSs) before and during hospitalization, explore the relationship between their use and various demographic and clinical variables, and compare the results with data from a similar 2000 study with particular interest in adherence to hospital formulary guidelines. Methods A cross-sectional observational survey of 326 hospitalized patients recruited from ten wards of the Ghent University Hospital, Gent, Belgium, with a patient interview and by evaluating medical and nursing files. Results In 30.7% of patients, the use of a HS before admission was reported. According to the patient interview, 33.1% used a HS during hospitalization. However, according to medical and nursing files, use of HSs in the hospital was 10% higher (43.3%). In 19.4% of patients who took HSs before admission, their use was discontinued in the hospital. In 15.6% of patients who took no HS before admission, a HS was started in the hospital, according to the formulary guidelines (data from files). There was a positive correlation between HS use in the hospital and older age, longer hospitalization, not coming from home, higher number of HSs taken before hospitalization, sleeping problems emerging during hospitalization, and central nervous system (CNS) disorders. In comparison with 2000, we registered a slight decrease in HS use during hospitalization and a decrease in the number of newly started patients. Conclusions The prevalence of HS use in our university hospital is high, mostly as a result of continuation of HSs started before admission, as there seems to be no general policy of active cessation. Compared with the survey performed 10 years ago, fewer hospitalized patients are newly started on HSs, and when this is the case, the formulary guidelines are followed.
Introduction
Hypnosedatives (HSs) are widely prescribed for treating insomnia and anxiety, but their long-term use is a reason for concern because of dependency, side effects, and cost [1] [2] [3] . Older patients are especially at risk for impaired cognitive and movement function, with an increased risk of inappropriate sedation, falls, and fractures [4] [5] [6] . It is well known that the worldwide use of HSs is high, both inside and outside the hospital [7] [8] [9] [10] . In Belgium, there is a high prevalence of HS prescription: surveys conducted in 2001, 2004, and 2008 [11] demonstrated an increasing use of HSs (reported use during the 2 weeks prior to the surveys was 5%, 8%, and 9%, respectively). The surveys found that the use of HSs increases with age (2004: 17% in patients ≥75 years). The Belgian Centre for Pharmacotherapeutic Information in its formulary gives guidance for treating acute and chronic insomnia and advises short-term use of benzodiazepines in case nonpharmacological approach is not helpful. However, the choice and dose of benzodiazepines that could be used are not mentioned, and no distinction is made between alprazolam or lorazepam and other benzodiazepines.
In 2000, we registered the use of HSs before and during hospitalization for 493 patients admitted to ten wards of our hospital. HSs were defined as benzodiazepines and benzodiazepine-like hypnotics (the so-called Z-drugs, i.e. zolpidem, zaleplon and zopiclone). We also included two tricyclic antidepressants, i.e., mianserine (ATC N06AX03) and trazodone (ATC N06AX05), as in our hospital, these are only used for HS purposes, as well as the antihistaminic dimetindene (ATC R06AB03). We found that 29% of these patients took an HS at home and that in 14% of them, the HS was discontinued during hospital stay. Furthermore, an HS was prescribed in the hospital in 45.2% of patients in total, and in 28.6% of the 493 patients, an HS was started [12] . In view of this high consumption, the hospital formulary guidelines (available upon request) were adapted and distributed throughout the hospital. Briefly, in case of sleeping problems, HSs are not recommended; in case of persisting and debilitating inner tension or adjustment problems, an intermediate-acting hypnosedative is recommended (e.g., lormetazepam or lorazepam) in a low dose and for a short period (preferably only once; maximum 1 or 2 weeks). These guidelines were published in the hospital formulary in 2003 and in 2005 as a printed version, which was sent to the medical staff and all head nurses. In 2007, an electronic drug bulletin was distributed with precise recommendations in case an HS is necessary, namely, to prescribe lormetazepam 1 mg for a short period and to stop newly started treatment before discharge. It was also stipulated in the drug bulletin that gradual discontinuation of HSs started before hospitalization should be considered. We repeated the registration in 2009 to evaluate whether the prevalence and dynamics of HS use was changed. Moreover, we wanted to collect more clinical data in order to search for risk factors for HS use that could orient us to more targeted actions.
Methods

Setting and study design
This prospective, observational, monocentric study was initiated by the Pharmacy and Therapeutic Committee of the Ghent University Hospital, Belgium, and performed on ten hospital wards after approval of the hospital Ethics Committee. The same definition of HS was used as in the previous study. The ten wards were those where the registration in 2000 was performed. These wards were included were cardiology, pneumology, nephrology, psychiatry, physical rehabilitation, maternity, head and neck surgery, thoracic and vascular surgery, plastic surgery, and abdominal surgery. Five of these wards had the highest and five the lowest consumption of HSs in 2000. The method was identical, namely, patient interview (after informed consent) by means of a questionnaire, and examination of the medical and nursing files. The interview used in 2009 was almost identical with the one used in 2000. The examination of the medical and nursing files was somewhat altered due to the implementation of electronic prescribing in half of the ten wards. The patients' health problems were also recorded. We included only patients who stayed at least two nights in the hospital, and interviewed all consecutively admitted patients to the ten wards during a sixweek period per ward.
Data collection
The use of HSs before and during hospitalization was measured by a patient interview and examination of the nursing and medical files. The interview took place on a random day during the patient's hospital stay, mostly about a week after admission, but this was different depending on the length of stay. Before the interview, the patient was informed about the purpose of the study and was asked for written informed consent. The interview (available upon request) consisted of 18 questions concerning sleeping problems and HS use before and during hospital stay, and additionally questioned the intended HS use after discharge. The information on HS use was completed with information from the medical and nursing files done at the moment of patient interview and at the moment of the discharge. In addition, the reason for hospitalization and health problems, based on a predefined list of 36 items, were registered. These 36 items were grouped into nine categories, namely, cardiovascular, respiratory, gastrointestinal, metabolic, blood-related, infection, malignancy, CNS pathology, and orthopedic and gait disorders. Metabolic disorders mainly concerned diabetes and acute and chronic renal insufficiency, gout, and osteoporosis; CNS pathology included, among others, dementia, depression, epilepsy, Parkinson's disease, and peripheral neuropathy. Demographic data concerned age, gender, origin (home, nursing home, other hospital), and length of stay. Data collection was performed by a hospital pharmacist.
Data analysis
Data were processed in Microsoft Access and transposed to SPSS version 17 for statistical analysis. The influence of age, residence before hospitalization, previous HS use on sleeping problems, and on the number of used HSs before and during hospitalization was assessed by a chi-square test (Fisher's exact test and linear-by-linear association) and logistic regression. The difference in HS use before, during, and after hospitalization was analysed by the Friedman test and the Wilcoxon signed-rank test. The McNemar test was used to determine the difference between sleeping problems before and during hospitalization. The influence of age and length of stay on sleeping problems was assessed by the Mann-Whitney U test. Spearman coefficient was used to analyze the correlation between age and length of stay on the one hand, and HS use on the other hand. The difference between HS use in 2000 and 2009 was assessed by a chisquare test.
Results
Demographics and health problems
During the 2.5 months of the survey, 330 patients were asked to participate; four did not accept. Demographic data of the 326 patients are shown in Table 1 . This population consisted of 155 women (47.5%) and 171 men (52.5%), mean age 53.5 [standard deviation (SD) 18.6] years. Twelve patients were transferred from a nursing home, 27 from another hospital, and 287 were living at home before admission. The mean length of hospital stay was 19.1 (SD 31.8; median 9) days. Four patients died during their hospital stay.
Patient distribution over the ten wards and length of stay per ward is presented in Table 2 . During the 6-week survey, around 40 patients were included per ward, except for the rehabilitation and psychiatry ward because of longer stay and less patient turnover as a consequence. The study duration was shorter for the abdominal surgery ward because of a delay in agreement for participation in the study.
Most patients in the study suffered from cardiovascular disorders (31.0%), followed by metabolic disorders (28.5%), malignancy (15.0%), respiratory disorders (14.1%), gastrointestinal disorders (9.5%), CNS disorders (9.2.%), orthopedic or gait disorders (7.7%), infection (4.9%), or blood-related disorders (2.8%).
Sleeping problems and hypnosedative use before admission
The patient interview revealed that 131 of patients (40.2%) suffered from sleeping problems before hospitalization; of them, 80 (61.1%) took a HS on a regular basis. Of the 195 patients who did not report sleeping problems before admission, 20 (10.3%) used a HS, resulting in 100 (30.7%) patients using HSs before admission ( Table 3) .
The main reasons for HS use mentioned by patients were a sleep initiation problem (n=68) or a sleep maintenance problem (n=36), as well as nervousness (n=30), fear (n= 7), and pain (n=4). Seventeen percent of patients that took HSs before admission had been given information on future discontinuation of HS use by the treating physician. According to the medical and nursing files, HSs were used before admission by 108 patients, with a total of 153 HSs. Thirty-three patients used more than one HS before admission (22 patients took two, ten took three, and one took four). Sleeping problems and hypnosedative use during hospitalization
Concerning sleeping problems in the hospital, 84 patients mentioned a combination of sleep initiation and sleep maintenance troubles (25.8%), 57 mentioned sleep maintenance problems (17.5%), and 38 mentioned sleep initiation problems (11.7%). In total, 179 patients (or 54.9 % of the study population) had difficulties sleeping in the hospital. According to the patient interview, 80 patients with and 28 without sleeping problems took an HS during hospitalization, resulting in a total of 108 patients, or 33.1% of the total study population ( Table 3 ). Ninety of the 108 patients were aware of the brand name. The main reasons for inhospital use of an HS mentioned by the patients were continuation of HS use before admission (n=51), sleeping problems emerging in the hospital (n=36), worsening of already existing sleeping problems in the hospital (n=7), fear (n=19), and pain (n=6). According to the patient interview, 35 patients were newly started on HSs during hospitalization (i.e., 15.5% of patients who did not take a HS before admission). Information about HS discontinuation in the future was given by the treating physician to two patients who were newly started on HSs during hospitalization (5.7%). According to the medical and nursing files, HS use during hospitalization was recorded for 141 patients (43.3%), with a total of 235 HSs, although not all HSs were used at the same time ( Table 4 ). For 18 patients (12.8%), the HS was prescribed upon request; for 83 HS patients (35.3%), a starting and stopping date was found. The linear-by-linear association showed a strong correlation between sleeping problems at home and the number of used HSs before, during, and after hospitalization. Sleeping problems emerging in the hospital were correlated with the number of HSs used in the hospital (p=0.002) but not with the number of HSs used before admission (p = 0.053). The Spearman correlation test revealed a positive correlation between HS use (before, during, and after hospitalization) and older age (p<0.001), and between HS use during hospitalization and length of stay (p<0.001). Furthermore, the linear-by-linear association showed a positive correlation between use of HSs in the hospital and not coming from home (p=0.032), a higher number of HSs taken before hospitalization (p<0.001), and CNS disorders (p<0.001). The highest prevalence of HS use was found on the rehabilitation, psychiatry, plastic surgery, thoracic and vascular surgery, and cardiology wards. When the patients of the maternity ward were excluded (there was no use of HSs found), nearly 50% of patients were taking a HS during hospitalization.
Hypnosedative use after discharge
Patient interviews revealed that in 27 of the 100 patients who declared taking a HS at home, the HS was stopped during hospitalization (27.0%). Two of these patients said 2000 2009 
Discussion
Strengths and weaknesses
The strength of this study is that the use of HSs before and during and the intended use after hospitalization were recorded accurately, using different sources, namely, a combination of patient interview and evaluation of medical and nursing files. This gave us the opportunity to report highly reliable data about HS use. Furthermore, we searched for risk factors (medical and demographic data) to identify patients with the greatest risk of prolonged HS use. Another strength is comparison with the study in 2000 using the same patient interview and including the same hospital wards, which allowed us to evaluate the evolution of HS use. Our study has several limitations. First, the formulary guideline was introduced only passively (by mail and by publication in the formulary) and was perhaps not widely enough known by prescribing physicians. It could have been more effective if it were implemented in a more proactive way, e.g., teaching or prospective advice. Second, the wards were selected according to HS use in 2000, namely, five wards with the highest and five with the lowest HS consumption. This means that some wards were excluded, either with routine active cessation or with inappropriate HS therapy (e.g., the geriatric and pneumology ward), which could have biased our results. Therefore, in the future, a hospital-wide survey would be more suitable, e.g., when electronic prescribing has been introduced in all wards. Another limitation is data at discharge, as HS use after discharge was extracted from the discharge documents; patient follow-up (e.g., by telephone call) was not performed.
Use of HSs before and during hospitalization
We found a discrepancy between patient interviews and medical and nursing files. The lower incidence of HS use reported by patients could be due to the fact that use of an HS as an anxiolytic was not perceived as sleep medication; furthermore, some patients, e.g., the severely ill, could not properly recall their medication use, and some HSs were started between the patient interview and consultation of Table 4 Incidence of hypnosedative (HS) use during hospitalization per ward patient files. One would expect, however, that the nursing file would correctly list every drug administration during hospitalization and would therefore be considered as the gold standard for drug use. However, we noticed that in the nursing and medical files, drugs recorded as being taken before admission were not always listed correctly (e.g., home medications to be continued), and sometimes, home medications were kept by the patients themselves (although this is against procedures). This resulted in loss of information about stopping dates in the patient files, which made correct interpretation of combined HS use very difficult. For instance, only for three of the seven patients for whom four HSs were prescribed can we be sure that the four HSs were combined at the same time. It is therefore likely that the real use of HSs was somewhere in between 33.1% (reported by the patients) and 43.3% (from medical and nursing files). Notwithstanding the difference between patient interview and file registration, the prevalence of HS use before and during hospitalization at our hospital is high.
In some published hospital studies, a large variability in HS use, from 15.7% to 45%, was reported [7, 8, [13] [14] [15] [16] [17] . The variability of the results could be due to the characteristics of the population studied, the method for data collection, and study duration. Furthermore, some of these studies were not performed recently, and HS use has probably changed over time. Comparison of the results from almost 10 years ago to those now in the same hospital is probably more meaningful and shows us that HS use during hospitalization has not decreased, mostly as a result of continuation of HSs started before admission, as there seems to be no general policy of active cessation. The positive news is that in comparison to 10 years ago, a smaller number of patients were newly started on HSs in the hospital, and when this was the case, the formulary guidelines were followed.
Risk factors
We explored the risk factors for HS use during hospitalization. As we found that information about discontinuation was provided for only two patients who were newly started, we can presume that the risk factors are predictive for prolonged use after discharge.
-Concerning demographic characteristics, HS use in the hospital was significantly higher in older patients, in patients who were not coming from home, and in patients who stayed longer in the hospital. The influence of age, length of stay, and comorbidities has also been found in previous studies [9, 10, 15, 16] . -Regarding diagnosis, there was a positive correlation between HS use in the hospital and CNS disorders, as well as HS use before admission.
-With regard to doctors' characteristics, HS use before admission could not be studied, but we explored in more detail the changes during hospitalization and found that relatively more HSs were newly started and fewer were actively stopped in surgical-ward patients compared with internal medicine wards. However, this should be interpreted with caution, as this was a monocentric study in which not all hospital wards were included.
Actions for the future Our results indicate that older patients who took HSs before admission and who suffer from comorbidities (especially psychological disorders) are at risk of prolonged HS use and adverse events as a consequence. Future preventive actions must take this population into consideration. We found that 143 of the 162 HS users (88.3%) were not informed by the treating physician about risk of dependence and were not encouraged to reduce HS use. The distribution of formulary guidelines for HS use has been useful for reducing HS initiation in the hospital, but another approach is needed to reduce the high HS use outsied the boundaries of the hospital setting. As mentioned, there is no general policy for active HS cessation in our hospital, and this is probably the same in many other hospitals. The finding that HSs are not often discontinued in the hospital can perhaps be explained by the fact that hospitalization in itself leads to anxiety and insomnia. Moreover, abrupt discontinuation is not recommended, as this could lead to withdrawal symptoms. Hospitalization could, however, be a good opportunity to optimize drug therapy, especially for older patients with several comorbidities [18] . Combined HS use should be discouraged to prevent adverse drug events, and clinicians should focus on short-term use in newly started patients and inform them of the need to restrict use in time. HS use could also be decreased by computer-based reminders to physicians and nursing staff regarding appropriate use [19] . Furthermore, a tapering scheme could be proposed to the patient and implemented after the acute phase of illness through electronic communication between the hospital and community-based physicians. This could especially be the case for patients admitted to surgical wards, were immediate discontinuation is perhaps not suitable but where evaluation of appropriate pharmacotherapy is not routinely applied. This action should be facilitated by the government through dissemination of guidelines for HS use and by setting up pilot projects in hospitals.
Several actions have already been taken in our hospital, including automatic stop orders in the electronic prescribing system for newly started HS use, clinical pharmacists' advice to lower HS doses in case patients are sleeping well and to change long-acting substances to intermediate acting HSs (e.g., a clinical pharmacist has been attached to the ward of thoracic vascular and plastic surgery, and more surgical wards should be scheduled for clinical pharmacy in the future). Furthermore, a protocol for active cessation is being set up, which uses a fast withdrawal scheme over 1 week, for patients >55 years suffering from different pathologies [20, 21] .
Conclusion
The prevalence of HS use in our university hospital is high, mostly as a result of HS continuation started before admission. In comparison with 10 years ago, HSs are started in fewer patients in the hospital, and when this is the case, the formulary guidelines are followed. There is still a long way to go to reduce the high consumption of HS, and strategies such as warnings through the electronic prescribing system, clinical pharmacy advice, and active tapering and discontinuation schemes for targeted patients should be explored.
